Case report: a successful re-challenge report of gls-010 (zimberelimab), a novel fully humanized mab to pd-1, in a case of recurrent endometrial cancer

HIGHLIGHTS

• who: Yeshan Chen from the University of Texas MD Anderson Cancer Center, United States have published the research work: Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer, in the Journal: (JOURNAL) of January/25,/2022

SUMMARY

With the introduction of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antibodies, a significant improvement of the efficacy was seen in numerous malignancies. Supported by a . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.